Pfizer Inc

Health Care
Biotechnology: Pharmaceutical Preparations
www.pfizer.com

Earnings Score
Moat Score
Safety Score

Market Cap $145.25B
PE 34
Debt $67.70B
Cash $1.15B
EV $211.80B
FCF $8.23B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$4.25B
EBIT	$3.90B
ROE	5%
ROA	2%
FCF	$8.23B
Equity	$92.56B
Growth Stability	10%
PE	34.16
PEG	-4.93
PB	1.57
P/FCF	17.66
P/S	2.42
Price/Cash	0.01
Debt/Equity	0.73
Debt/FCF	8.23
Net Margins	17%
Gross Margins	68%
Op. Margins	6%
Earnings CAGR	4%
Sales Growth YoY	34%
Sales Growth QoQ	33%
Sales CAGR	5%
FCF CAGR	-3%
Equity CAGR	5%
Earnings Stability	0.03
Earnings Growth YoY	-287%
Earnings Growth QoQ	11K%
Earnings CAGR 5Y	-7%

Sales CAGR 5Y	8%
FCF CAGR 5Y	-14%
Equity CAGR 5Y	11%
Earnings CAGR 3Y	-20%
Sales CAGR 3Y	-20%
FCF CAGR 3Y	-54%
Equity CAGR 3Y	4%
Market Cap	$145.25B
Revenue	$60.11B
Dividend Yield	7%
Payout Ratio	222%
Assets	$219.48B
Total Debt	$67.70B
Cash	$1.15B
Shares Outstanding	5.65B
EV	211.8B
Earnings Score	6%
Moat Score	56%
Safety Score	49%
Final Score	37%
Working Capital	12M
Current Ratio	1
Gross Profit	$40.61B
Shares Growth 3y	1%
Equity Growth QoQ	5%
Equity Growth YoY	-5%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

SEC Filings

Direct access to Pfizer Inc (PFE) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 29
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Oct 01
- 10-Q Jul 02
- 10-Q Apr 02
2022
- 10-K Dec 31
- 10-Q Oct 02
- 10-Q Jul 03
- 10-Q Apr 03

Sector Comparison

How does Pfizer Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Pfizer Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 4%

Stability 3%

loading chart...

Pfizer Inc Discounted Cash Flow

Fully customizable DCF calculator online for Pfizer Inc.

Years

Calculation mode

= $68B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$8.2B	$8B	$7.8B	$7.6B	$7.3B	$7.1B	$6.9B	$6.7B	$6.6B	$6.4B	$6.2B	$62B
DCF		$7.3B	$6.4B	$5.7B	$5B	$4.4B	$3.9B	$3.5B	$3.1B	$2.7B	$2.4B	$24B
Value	$68B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	18%	14%	14%	41%	21%	31%	23%	27%	31%	4%	17%
ROA	-	6%	6%	7%	7%	11%	5%	13%	18%	0%	2%
ROE	-	11%	12%	30%	17%	26%	15%	28%	33%	2%	5%

Good Net Margins (16.62%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	2.97	2.99	3	3.03	5.01	3.28	1.27	1.38	15	8.23
Debt over Equity	0.51	0.6	0.7	0.61	0.65	0.82	0.63	0.5	0.37	0.81	0.73
Growth Stability	-	-	-	100%	94%	100%	59%	100%	100%	10%	10%

Bad Debt/FCF ratio (8.23)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Good Debt/Equity ratio (0.73)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (10%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-2%	8%	-1%	2%	-4%	-20%	95%	23%	-42%	8%
Earnings YoY growth	-	-24%	4%	195%	-48%	46%	-41%	129%	43%	-93%	-7%
Equity YoY growth	-	-9%	-8%	20%	-11%	-0%	0%	22%	24%	-7%	11%
FCF YoY growth	-	-16%	7%	3%	-5%	-24%	17%	149%	-14%	-82%	-14%